Les Dutton, Ph.D., will be awarded the 2013 John Scott Award next week. He will be honored with a medal, certificate, and $12,000 for his "work on the elementary processes of oxidation-reduction and the diverse biological events coupled to it." Dutton is the Eldridge Reeves Johnson Professor of Biochemistry and Biophysics, the director of the Johnson Foundation for Molecular Biophysics, a Fellow of the Royal Society, and former chair of the Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania. And an accomplished artist, but more on that later.
Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer and control tumor progression. With the exception of melanoma, it has been difficult to identify and isolate the tumor-reactive T cells from common cancers, however, the ability to do so could be used to fight a patient’s own cancer.
With this zoomed-in view, the Abramson Family Cancer Research Institute (AFCRI) lab of Celeste Simon, PhD, and postdoctoral fellow, T.S. Karin Eisinger-Mathason PhD, report in Cancer Discovery about the potential of the collagen-modifying enzyme PLOD2 as a new therapeutic target for the treatment of metastatic undifferentiated pleomorphic sarcoma.
To show its gratitude to all laboratory professionals, the department of Pathology and Laboratory Medicine celebrated Medical Laboratory Professionals Week April 22-26, with a host of activities, such as Phillies Night, in appreciation of all the hard work and dedication of the hundreds of staff and faculty members working in more than 30 different laboratories across the Penn campus.
Penn Medicine will play a starring role in the Philadelphia Science Festival again this year. The Festival is a citywide collaboration showcasing science and technology every April. This year it runs from April 19 - 28, 10 days to celebrate the region’s strengths in science and technology, bringing together more than 100 partners from academia to museums to restaurants.
To celebrate February as American Heart Month, the News Blog is highlighting some of the latest heart-centric news and stories from all areas of Penn Medicine. “I know this sounds like a cliché, but one of the main reasons I’m interested in learning about the genetic basis of heart...
“We showed for the first time that clotting is reversible,” says John Weisel, Ph.D., professor of Cell and Developmental Biology, in contrast to a long-standing assumption that it isn’t. Weisel and colleagues showed how these sometimes dangerous knots of protein and cells are actually a dynamic, mutable structure this month...
A “Modest Proposal:” Spreading the Wealth from Intellectual Property to Encourage New Players in Drug Development
Garret FitzGerald, MD, chair of the Department of Pharmacology and Director of the Institute for Translational Medicine & Therapeutics, Perelman School of Medicine at the University of Pennsylvania, has long said the current drug-development system in the United States is in need of change, “representing an unsustainable model.” He suggests...
Greg Sonnenberg, PhD, research associate in the Division of Gastroenterology and the Institute for Immunology, is one of 14 early-career scientists supported this year with an NIH Director's Early Independence Award. These support exceptional early-career scientists to move directly into independent research positions by essentially omitting the traditional post-doctoral training period.
The use of DNA in forensics is powerful yet subject to uncertainties. Jennifer Wagner, JD, PhD, a Research Associate at the Center for the Integration of Genetic Healthcare Technologies at the University of Pennsylvania (Penn CIGHT), and Sara Katsanis, MS, an Associate in Research at the Duke Institute for Genome Sciences & Policy at Duke University (Duke IGSP) conducted an exhaustive search of the literature and genome databases to put forensic markers used in the Combined DNA Index System (CODIS) into a context of current understanding of the human genome. Their findings are available in an early online issue of the Journal of Forensic Sciences.
This summer, Garret FitzGerald, MD, chair of the Institute for Translational Medicine and Therapeutics (ITMAT), testified at a briefing on the Hill organized by American Association for the Advancement of Science that the current drug-development system in the United States is flawed and in need of change.